;
Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Anthim obiltoxaximab: Phase III data

    Elusys Therapeutics Inc., Pine Brook, N.J. Product: Anthim obiltoxaximab (ETI-204) Business: Infectious Molecular target: Bacillus anthracis protective antigen Description: High-affinity humanized mAb against the …

    Published on 10/13/2014
  • APD421: Phase III data

    Acacia Pharma Ltd., Cambridge, U.K. Product: APD421 (formerly ACA1421) Business: Gastrointestinal Molecular target: Dopamine D2 receptor; Dopamine D3 receptor Description: IV formulation of amisulpride, an off-patent …

    Published on 10/13/2014
  • ARC-520: Phase IIa data

    Arrowhead Research Corp. (NASDAQ:ARWR), Pasadena, Calif. Product: ARC-520 Business: Infectious Molecular target: NA Description: Short interfering RNAs targeting 2 regions of the HBV genome conjugated to N-…

    Published on 10/13/2014
  • Asunaprevir/daclatasvir/BMS-791325: Phase III data

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Asunaprevir/daclatasvir/BMS-791325 Business: Infectious Molecular target: HCV NS3 protease; HCV NS5A protein Description: Fixed-dose oral combination of …

    Published on 10/13/2014
  • Asunaprevir/daclatasvir/BMS-791325: Phase III data

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Asunaprevir/daclatasvir/BMS-791325 Business: Infectious Molecular target: HCV NS3 protease; HCV NS5A protein Description: Fixed-dose oral combination of …

    Published on 10/13/2014
  • Brincidofovir: Preliminary Phase III data

    Chimerix Inc. (NASDAQ:CMRX), Durham, N.C. Product: Brincidofovir (CMX001) Business: Infectious Molecular target: NA Description: Oral lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations …

    Published on 10/13/2014
  • EBI-005: Phase II data

    Eleven Biotherapeutics Inc. (NASDAQ:EBIO), Cambridge, Mass. Product: EBI-005 Business: Inflammation Molecular target: Interleukin-1 (IL-1) Description: IL-1 receptor antagonist Indication: Treat allergic conjunctivitis …

    Published on 10/13/2014
  • Gamma-retrovirus gene therapy: Phase I/II data

    Hopital Necker-Enfants Malades, Paris, France Product: Gamma-retrovirus gene therapy Business: Hematology Molecular target: NA Description: Gene therapy comprised of bone marrow-derived CD34+ cells transduced with the …

    Published on 10/13/2014
  • Hydrocodone bitartrate ER: Clinical trial data

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Product: Hydrocodone bitartrate ER (CEP-33237) Business: Neurology Molecular target: NA Description: Twice-daily, acetaminophen-free hydrocodone …

    Published on 10/13/2014
  • ISIS-SMNRx: Additional Phase II data

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Product: ISIS-SMNRx Business: Neurology Molecular target: Survival of motor neuron 2 centromeric (SMN2) Description: Antisense oligonucleotide that modulates …

    Published on 10/13/2014
  • ISIS-SMNRx: Additional Phase II data

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Product: ISIS-SMNRx Business: Neurology Molecular target: Survival of motor neuron 2 centromeric (SMN2) Description: Antisense oligonucleotide that modulates …

    Published on 10/13/2014
  • Keytruda pembrolizumab: Additional Phase Ib data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Keytruda pembrolizumab (MK-3475) (formerly lambrolizumab) Business: Cancer Molecular target: Programmed cell death 1 (PDCD1) (PD-1) (CD279) Description: …

    Published on 10/13/2014
  • Metadoxine ER: Phase III data

    Alcobra Ltd. (NASDAQ:ADHD), Tel Aviv, Israel Product: Metadoxine ER (MDX) (MG01CI) Business: Neurology Molecular target: Serotonin (5-HT2B) receptor Description: Extended-release formulation of metadoxine, a selective …

    Published on 10/13/2014
  • MOB-015: Phase II final data

    Moberg Pharma AB (SSE:MOB), Bromma, Sweden Product: MOB-015 Business: Infectious Molecular target: NA Description: Topical formulation of terbinafine Indication: Treat onychomycosis Endpoint: Proportion of patients with…

    Published on 10/13/2014
  • MyPath Melanoma test: Pivotal trial data

    Myriad Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah Product: MyPath Melanoma test Business: Diagnostic Molecular target: NA Description: Assay consisting of a 23-gene panel to differentiate malignant melanoma from …

    Published on 10/13/2014
  • REC 0482: Additional Phase II data

    Nymox Pharmaceutical Corp. (NASDAQ:NYMX), Saint-Laurent, Quebec Recordati S.p.A. (Milan:REC), Milan, Italy Product: REC 0482, NX-1207 Business: Cancer Molecular target: Undisclosed Description: Undisclosed Indication: …

    Published on 10/13/2014
  • Reslizumab: Phase III data

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Product: Reslizumab (formerly Cinquil) Business: Inflammation Molecular target: Interleukin-5 (IL-5) Description: Humanized mAb against IL-5 …

    Published on 10/13/2014
  • Reslizumab: Phase III data

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Product: Reslizumab (formerly Cinquil) Business: Inflammation Molecular target: Interleukin-5 (IL-5) Description: Humanized mAb against IL-5 …

    Published on 10/13/2014
  • Ultibro Breezhaler indacaterol/glycopyrronium bromide: Additional Phase III data

    Sosei Group Corp. (Tokyo:4565), Tokyo, Japan Vectura Group plc (LSE:VEC), Chippenham, U.K. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Ultibro Breezhaler indacaterol/glycopyrronium bromide (Ulunar …

    Published on 10/13/2014
  • Vosaroxin: Phase III data

    Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS), South San Francisco, Calif. Product: Vosaroxin (AG-7352) (formerly voreloxin, SNS-595) Business: Cancer Molecular…

    Published on 10/13/2014
  • Xeglyze: Phase III data

    Hatchtech Pty. Ltd., Melbourne, Australia Product: Xeglyze (formerly DeOvo) Business: Infectious Molecular target: NA Description: Ovicidal head lice treatment containing abametapir Indication: Treat lice Endpoint: …

    Published on 10/13/2014
  • Adcetris brentuximab vedotin: Phase III data

    Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Adcetris brentuximab vedotin (SGN-35) Business: Cancer Molecular target: CD30 Description: Antibody-…

    Published on 10/6/2014
  • Andexanet alfa: Phase III data

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA), South San Francisco, Calif. Product: Andexanet alfa (PRT4445, PRT064445) Business: Cardiovascular Molecular target: NA Description: Recombinant protein that reverses the …

    Published on 10/6/2014
  • Copaxone glatiramer acetate: Phase IIIb data

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Copaxone glatiramer acetate Business: Autoimmune Molecular target: Major histocompatibility …

    Published on 10/6/2014
  • Dalantercept: Interim Phase II data

    Acceleron Pharma Inc. (NASDAQ:XLRN), Cambridge, Mass. Product: Dalantercept (ACE-041) Business: Cancer Molecular target: Activin receptor-like kinase 1 (ACVRL1) (ALK1) (HHT2) Description: Angiogenesis inhibitor that …

    Published on 10/6/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993